Antimullerian Hormone as an Indicator fo Ovarian Response in Women Receiving Long GnRH Agonist Protocol in Intracytoplasmic Sperm Injection Cycles
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Ain Shams Maternity Hospital
- Enrollment
- 66
- Primary Endpoint
- Difference between AMH levels between good and poor responders in young patients receiving long GnRH agonist protocol for ICSI.
Study Overview
Brief Summary
Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance.
Investigators explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. Methods: This prospective analysis compiled data of 66 females, receiving ICSI treatment from April 2016 to October 2017. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 20 Years to 40 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age:20-40 years old
- •BMI:20-40kg/m
- •Normal baseline hormonal profile (on the 2nd day of the cycle)
- •FSH: 2.5-10.2mlU/ml
- •LH:1.9-12.5mlU/ml
- •Estradiol (E2): <50pg/ml
- •No Endometriosis by laparoscopy
- •No prior ovarian surgery; overectomy, ovariectomy or oophrectomy
- •Female subjects who have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotrophin releasing hormone (GnRH) agonist therapy
Exclusion Criteria
- •Age: <20 or >40 years old
- •BMI: <20 or >40kg/m
- •Female subjects with any contraindication for pregnancy.
- •Female subjects with history of tumors of the hypothalamus & pituitary gland.
- •Female subjects with history of ovarian, uterine or mammary cancer.
- •Female subjects with history of hypersensitivity to the active substance of the medications used for ovarian stimulation.
- •Abnormal baseline hormonal profile
- •Endometriosis by laparoscopy
- •Previous ovarian surgery; overectomy, ovariectomy or oophrectomy
- •Female subjects with abnormal gynecological bleeding of unknown etiology
Outcomes
Primary Outcomes
Difference between AMH levels between good and poor responders in young patients receiving long GnRH agonist protocol for ICSI.
Time Frame: 1 month (1 cycle)
Measurement of AMH level in patients undergoing controlled ovarian stimulation prior to ICSI using long GnRH agonist protocol. Level will be compared between good and poor responders.
Secondary Outcomes
No secondary outcomes reported
Investigators
Ahmed Mohammed Selim
Doctor
Ain Shams Maternity Hospital